HLS Therapeutics Inc (HLS)

HLS Therapeutics Reports Annual Meeting Results

HLS Therapeutics Reports Annual Meeting Results Canada NewsWire TORONTO, June 26, 2026 TORONTO, June 26, 2026 /CNW/ - HLS Therapeutics...

HLS Therapeutics Announces Normal Course Issuer Bid

HLS Therapeutics Announces Normal Course Issuer Bid Canada NewsWire TORONTO, June 23, 2026 TORONTO, June 23, 2026 /CNW/ - HLS Therapeutics...

HLS Therapeutics Announces Q1 2026 Financial Results

HLS Therapeutics Announces Q1 2026 Financial Results Canada NewsWire TORONTO, May 15, 2026 Q1 2026 revenue of $12.9 million, up 2...

HLS Therapeutics to Host Q1 2026 Financial Results Conference Call

HLS Therapeutics to Host Q1 2026 Financial Results Conference Call Canada NewsWire TORONTO, May 1, 2026 TORONTO, May 1, 2026 /CNW/ - HLS...

HLS Therapeutics to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

HLS Therapeutics to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire TORONTO, April 14, 2026...

HLS Therapeutics Announces Fiscal 2025 Financial Results

HLS Therapeutics Announces Fiscal 2025 Financial Results Canada NewsWire TORONTO, March 12, 2026 Adjusted EBITDA1 grew 18% to $19.6...

/C O R R E C T I O N -- HLS Therapeutics Inc./

/C O R R E C T I O N -- HLS Therapeutics Inc./ Canada NewsWire TORONTO, March 5, 2026 In the news release, HLS Therapeutics Announces...

HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease

HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of...

HLS Therapeutics to Host Fiscal 2025 Financial Results Conference Call

HLS Therapeutics to Host Fiscal 2025 Financial Results Conference Call Canada NewsWire TORONTO, Feb. 26, 2026 TORONTO, Feb. 26, 2026 /CNW/...

HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular...

HLS Therapeutics Announces Q3 2025 Financial Results

HLS Therapeutics Announces Q3 2025 Financial Results Canada NewsWire TORONTO, Nov. 13, 2025 Adjusted EBITDA grew 19% in Q3 and 25...

HLS Therapeutics to Host Q3 2025 Financial Results Conference Call

HLS Therapeutics to Host Q3 2025 Financial Results Conference Call Canada NewsWire TORONTO, Oct. 30, 2025 TORONTO, Oct. 30, 2025 /CNW/...

HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

HLS Therapeutics Announces New Credit Agreement

HLS Therapeutics Announces New Credit Agreement Canada NewsWire TORONTO, Aug. 20, 2025 CAD $79 million term loan replaces USD $56 million term...